Biotechnology

South Korean pharma giant Yuyu Pharma invests in James & Ella, the UK's top freeze-dried pet food brand, signaling a major push into the booming pet wellness market.

New preclinical data suggests Arcellx's CAR T therapy may offer a safer profile than rivals, potentially avoiding severe neurological side effects.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

A world-first trial for personalized mRNA vaccines offers new hope for children with aggressive brain tumors, a mission born from a father's own fight.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

Caribou Biosciences unveils new data showing its 'off-the-shelf' CAR-T cells achieve deep, lasting responses in lymphoma and myeloma clinical trials.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

With a key cancer drug awaiting FDA review and pivotal data imminent, Celcuity faces investors at a critical juncture. What will they be looking for?

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

Final Phase 1b data for Kodiak Sciences' KSI-101 suggests a potential breakthrough for macular edema, a condition lacking dedicated biologic therapies.

A new AI-driven approach to cancer therapy promises to breach the blood-brain barrier, offering hope for treating aggressive tumors where others have failed.

Landmark legislation targets pharmacy benefit managers to end restrictive practices, promising better access for patients with complex diseases.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.